LYMZENTY
Live / Applied — Revived — awaiting further action (as of 15 Sept 2026)
What this means for you
Not registered yet, but its 06 Mar 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98435992
- Mark type
- Word mark
- Filed
- 06 Mar 2024
- Published for opposition
- 13 May 2025
- Attorney of record
- Marilyn F. Kelly
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs being pharmaceutical preparations for the treatment of cancer; anticoagulants; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; Pharmaceutical preparations for human use for the treatment of cystic fibrosis
Owner
- Celgene Corporation, Princeton, NJ, US
- Celgene Corporation, Princeton, NJ, US
Board proceedings on this mark
- Opposition No. 91300248 — Provepharm Life Solutions v. Celgene Corporation, filed 10 Jul 2025 (Terminated)
- Extension of Time to Oppose No. 98435992 — PROVEPHARM LIFE SOLUTIONS v. Celgene Corporation, filed 06 Jun 2025 (Terminated)
Prosecution history
- 15 Sept 2026 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 15 Sept 2026 — NOTICE OF REVIVAL - E-MAILED
- 15 Sept 2026 — PETITION TO REVIVE-GRANTED
- 15 Sept 2026 — TEAS PETITION TO REVIVE RECEIVED
- 14 Sept 2026 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 14 Sept 2026 — ABANDONMENT - NO USE STATEMENT FILED
- 10 Feb 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 10 Feb 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 10 Feb 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 10 Feb 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Jan 2026 — TTAB RELEASE CASE TO TRADEMARKS
- 02 Jan 2026 — OPPOSITION TERMINATED NO. 999999
- 02 Jan 2026 — OPPOSITION DISMISSED NO. 999999
- 12 Jul 2025 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 10 Jul 2025 — OPPOSITION INSTITUTED NO. 999999